Gland Pharma pays ₹1.40 lakh fine for technical breach of director norms
- Gland Pharma paid a total penalty of ₹1.40 lakh to NSE and BSE
- The fine relates to a 34-day technical breach of SEBI LODR Regulation 17(1A)
- Each exchange levied a fine of ₹70,000 excluding applicable GST
- The company settled the full amount suo motu ahead of final notice receipt
*this image is generated using AI for illustrative purposes only.
Gland Pharma has paid a total penalty of ₹1.40 lakh to the National Stock Exchange and Bombay Stock Exchange for a technical non-compliance with director appointment regulations. The company settled the fines suo motu to ensure timely closure of the matter.
Regulatory Breach Details
The penalty stems from a violation of Regulation 17(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company appointed Mr. William Keller as an Independent Director on June 15, 2026, subject to shareholder approval via special resolution.
The shareholders passed the resolution through postal ballot on July 18, 2026. However, this process resulted in a technical breach for a period of 34 days. This duration included the mandatory 30-day postal ballot or e-voting period required between the board meeting and the final date of the ballot.
Penalty Breakdown
The stock exchanges levied fines on Gland Pharma for the alleged non-compliance. The company disclosed the breakdown of the penalties in its filing dated September 13, 2026.
| Exchange | Fine Amount |
|---|---|
| National Stock Exchange | ₹70,000 |
| Bombay Stock Exchange | ₹70,000 |
| Total (excluding GST) | ₹1.40 lakh |
Compliance Measures
Gland Pharma’s Board of Directors noted the fines at its meeting held on September 13, 2026. The board confirmed that the company had already obtained the requisite special resolution from shareholders, thereby rectifying the compliance gap.
The board advised management to strengthen internal processes and compliance mechanisms to prevent recurrence. It emphasized strict adherence to SEBI LODR regulations in both letter and spirit.
Payment Status
As of the quarter ended June 30, 2026, the company had received notices for only part of the total fine amount. Notices pertaining to the balance amount were expected in November 2026 for the quarter ending September 30, 2026. Despite this, Gland Pharma paid the entire fine amount at one time to demonstrate its commitment to regulatory compliance.
Historical Stock Returns for Gland Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.83% | +0.50% | +9.56% | +73.10% | +53.60% | 0.0% |
Will Gland Pharma implement third-party compliance audits to prevent future technical breaches under SEBI LODR regulations?
How might this settlement impact investor confidence in Gland Pharma's corporate governance practices ahead of upcoming quarterly earnings?
Are there any pending regulatory reviews or additional disclosures required from SEBI regarding the appointment of Mr. William Keller?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
